Compare · Health Care
Bristol Myers Squibb vs. Merck: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Merck's revenue of $65.0B was about 1.3 times Bristol Myers Squibb's $48.2B (Cityfort calculation: one divided by the other).
Bristol Myers Squibb's largest segment is Growth Portfolio, 54.8% of revenue in FY2025; Merck's largest segment is Pharmaceutical, 89.4% of revenue in FY2025.
United States brought in 69.1% of Bristol Myers Squibb's revenue in FY2025; United States brought in 56.2% of Merck's revenue in FY2025.
Bristol Myers Squibb's largest payer group is Customers in the US, 69.1% of revenue (FY2025); Merck's largest payer group is Customers in the US, 56.2% of revenue (FY2025).
Neither page lists the other among its competitors.
Each company in 5 points
Bristol Myers Squibb
1 · What it sells
Bristol Myers Squibb sells prescription medicines, and the blood thinner Eliquis brought in $14.4 billion and the cancer medicine Opdivo $10.0 billion of its $48.2 billion of FY2025 revenue.
Sources and detail on the Bristol Myers Squibb page2 · Who pays it
BMS reports no net revenue by customer or final payer; by location, in FY2025 US customers paid 69.1% of revenue, customers elsewhere 28.7% and partners and royalty payers 2.3%.
Sources and detail on the Bristol Myers Squibb page3 · What it keeps from $100
Of every $100 of FY2025 revenue, BMS kept $14.6 as net income after $7.7 of charges for bought research, and operating income, a Cityfort calculation from the FY2025 10-K, was $20.8.
Sources and detail on the Bristol Myers Squibb page4 · Where the operating profit comes from
BMS reports one segment and no profit by product, so profit comes from the whole portfolio, where the Growth Portfolio of newer medicines was 54.8% of FY2025 revenue.
Sources and detail on the Bristol Myers Squibb page5 · The one thing to watch
Eliquis and Opdivo were 30.0% and 20.9% of BMS's FY2025 revenue, and BMS estimates US exclusivity for both ends in 2028.
Sources and detail on the Bristol Myers Squibb page
Merck
1 · What it sells
Merck sells prescription medicines, vaccines and animal health products, and Keytruda, a cancer medicine, brought in $31.6 billion of its $65.0 billion of FY2025 sales.
Sources and detail on the Merck page2 · Who pays it
Merck reports no sales by customer or final payer; by location, in FY2025 the US paid 56.2% of sales, Europe, the Middle East and Africa 22.4% and other regions 21.4%.
Sources and detail on the Merck page3 · What it keeps from $100
Of every $100 of FY2025 sales, Merck kept $28.1 as net income after $24.3 of research, and operating income, a Cityfort calculation from the FY2025 10-K, was $32.6.
Sources and detail on the Merck page4 · Where the operating profit comes from
Pharmaceutical segment profit was $45.8 billion in FY2025 and Animal Health's $2.1 billion, before $26.8 billion of costs Merck keeps outside its segments, such as most research and amortization.
Sources and detail on the Merck page5 · The one thing to watch
Keytruda was 49% of Merck's FY2025 sales, and Merck expects a Medicare set price for it from Jan 1, 2029, after its key US patent runs out in 2028.
Sources and detail on the Merck page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
Bristol Myers Squibb
Where $100 went · FY2025
| Research and development | $20.6 |
|---|---|
| Selling, general and administrative | $15.1 |
| Cost of products sold | $28.9 |
| Acquired research (Acquired IPRD) | $7.7 |
| Amortization of acquired intangibles | $6.9 |
| Income tax and other expense | $6.1 |
| Kept as net income | $14.6 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $48.2 billion × 100. Other items were a net cost, so no other income is added. Lines are rounded.
Merck
Where $100 went · FY2025
| Research and development | $24.3 |
|---|---|
| Selling, general and administrative | $16.5 |
| Cost of making products | $25.2 |
| Restructuring and other items | $1.6 |
| Income tax and small items | $4.3 |
| Kept as net income | $28.1 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 of sales in FY2025: each line = line ÷ $65.0 billion × 100. Other items were a net cost, so no other income is added. Lines are rounded and add to 100.
Line items differ because each company groups its costs its own way in its filings. Only on Bristol Myers Squibb's receipt: Cost of products sold; Acquired research (Acquired IPRD); Amortization of acquired intangibles; Income tax and other expense. Only on Merck's receipt: Cost of making products; Restructuring and other items; Income tax and small items.
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
Bristol Myers Squibb
Merck
See the numbers
Net income
Bristol Myers Squibb
Merck
See the numbers
Free cash flow
Bristol Myers Squibb
Merck
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
Bristol Myers Squibb
- Revenue, per year
- +1.0%
- Net income, per year
- +0.2%
Merck
- Revenue, per year
- +7.5%
- Net income, per year
- +8.8%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Bristol Myers Squibb
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $13.1B | $12.2B | +6.9% |
| Net income | $2.2B | $2.2B | −1.8% |
Merck
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $18.1B | $17.3B | +4.7% |
| Net income | $5.1B | $5.8B | −12.4% |
Sources: Bristol Myers Squibb S15, S8, S14, S1, S13, S7, S12, S6, S11, S5 · Merck S18, S9, S16, S17, S1, S15, S8, S14, S7, S12, S6
Who pays each company
Bristol Myers Squibb
- Customers in the US · 69.1% of revenue69.1% of FY2025 revenue ($33.3 billion). Most US sales go through three wholesalers. Shares here are by location, because BMS does not report net revenue by customer or final payer.
- Customers outside the US · 28.7% of revenue28.7% of FY2025 revenue ($13.8 billion).
- Partners and royalty payers · 2.3% of revenue2.3% of FY2025 revenue ($1.1 billion): alliance and royalty revenue that BMS does not assign to a region.
Merck
- Customers in the US · 56.2% of revenue56.2% of FY2025 sales ($36.5 billion). Most US sales go through wholesalers. Shares here are by location, because Merck does not report sales by customer or final payer.
- Europe, Middle East and Africa · 22.4% of revenue22.4% of FY2025 sales ($14.6 billion).
- Asia Pacific, including Japan and China · 11.7% of revenue11.7% of FY2025 sales: Japan $2.7 billion, China $1.9 billion and the rest of Asia Pacific $3.0 billion. China fell from $6.8 billion in FY2023.
- Latin America · 5.2% of revenue5.2% of FY2025 sales ($3.4 billion).
- Other · 4.4% of revenue4.4% of FY2025 sales ($2.9 billion), the remainder Merck does not assign to these regions.
Revenue by segment
Bristol Myers Squibb
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Growth Portfolio | $26.4B | 54.8% |
| Legacy Portfolio | $21.8B | 45.2% |
Merck
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceutical | $58.1B | 89.4% |
| Animal Health | $6.4B | 9.8% |
| Other | $515M | 0.8% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
Bristol Myers Squibb
FY2025
- United States69.1%
- International28.7%
- Other (alliance and royalty revenue not assigned to a region)2.3%
Merck
FY2025
- United States56.2%
- Europe, Middle East and Africa22.4%
- Latin America5.2%
- Asia Pacific (excluding Japan and China)4.6%
- Other4.4%
- Japan4.2%
- China3.0%
Debt and cash
Bristol Myers Squibb
- Debt
- $42.9B
- Cash and investments
- $13.0B
On Sep 30, 2026.
At Sep 30, 2026 BMS's debt exceeded its cash and marketable debt securities by $29.9 billion, as stated in the Q3 FY2026 10-Q, down from $38.5 billion at Dec 31, 2024. That is about 2.8 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).
Merck
- Debt
- $53.8B
- Cash and investments
- $9.6B
On Sep 30, 2026.
At Sep 30, 2026 Merck's debt exceeded its cash by $44.2 billion, up from $34.8 billion at Dec 31, 2025. That is about 2.4 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).
Sources: Bristol Myers Squibb S5, S1, S2, S8 · Merck S6, S1, S4, S9, S26, S27
Who owns each company
Bristol Myers Squibb
- One class of shares.
- Officers and directors as a group: 0.1% of shares (as of Mar 12, 2026).
- Vanguard Capital Management: 7.5% (as of Apr 29, 2026).
- BlackRock, Inc.: 7.1% (as of Apr 17, 2025).
- State Street Corporation: 5.0% (as of Aug 7, 2026).
- 2 more holders on the Bristol Myers Squibb page.
Merck
- One class of shares.
- Officers and directors as a group: 0.2% of shares (as of Feb 28, 2026).
- BlackRock, Inc.: 8.2% (as of Jan 26, 2024).
- Vanguard Capital Management: 7.5% (as of Apr 30, 2026).
- The Vanguard Group: 0.0% (as of Mar 27, 2026).
Sources: Bristol Myers Squibb S19, S5, S21, S23, S20 · Merck S22, S6, S23, S24
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Bristol Myers Squibb
- Patents on the main medicines
BMS estimates US exclusivity for Eliquis and Opdivo to 2028, Reblozyl to 2031, Breyanzi to 2033 and Camzyos to 2036. Revlimid and Pomalyst already face US generics.
- Research spending
BMS spent $10.0 billion on research and development in FY2025, 20.6% of revenue, plus $3.7 billion on acquired research.
- Newer products
The Growth Portfolio rose from $16.8 billion in FY2022 to $26.4 billion in FY2025, 54.8% of revenue.
- Pricing power
A Medicare set price applies to Eliquis from Jan 1, 2026 and to Pomalyst from Jan 1, 2027. Under a December 2025 agreement with the US government, Eliquis is free to Medicaid from Jan 1, 2026.
Merck
- Patents on the main medicines
Keytruda's key US patent runs to 2028 and its EU patent to 2031. Keytruda Qlex's US patent runs to 2043. Januvia and Bridion lost US protection in 2026.
- Research spending
Merck spent $15.8 billion on research and development in FY2025, 24.3% of sales, and about 24,700 employees worked in research.
- Global reach
43.8% of FY2025 sales came from outside the US, across Europe, Asia Pacific and Latin America.
- Pricing power
Medicare set a Januvia price from Jan 1, 2026. Merck expects Keytruda to be selected in 2027 for a set price from Jan 1, 2029. Merck also signed a three-year pricing agreement with the US government in December 2025.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Bristol Myers Squibb
- Eliquis · Working: on track against what the company said$4.7B in Q3 FY2026, up 25%
- Opdivo and Opdivo Qvantig · Mixed: partly on track$2.7B in Q3 FY2026
- Breyanzi · Working: on track against what the company said$526M in Q3 FY2026, up 46%
- Camzyos · Working: on track against what the company said$420M in Q3 FY2026, up 42%
- Reblozyl · Working: on track against what the company said$750M in Q3 FY2026, up 22%
- Cobenfy (from Karuna) · Early: too early to judge$57M in Q3 FY2026
- Zenbexus and other new approvals · New: recently announcedFDA approval on Aug 13, 2026
Merck
- Keytruda and Keytruda Qlex · Working: on track against what the company said$8.6B in Q3 FY2026, up 6%
- Keytruda Qlex (under the skin) · New: recently announced$830M in Q3 FY2026
- Winrevair · Working: on track against what the company said$694M in Q3 FY2026, up 93%
- Capvaxive · Mixed: partly on track$263M in Q3 FY2026, up 8%
- Gardasil · Mixed: partly on track$2.0B in Q3 FY2026, up 14%
- Ohtuvayre (from Verona Pharma) · New: recently announced$184M in Q3 FY2026
- Bought drug programs · Early: too early to judge$9.2B and $6.8B deals in 2026
Sources: Bristol Myers Squibb S5, S11, S1, S15, S3, S12, S2 · Merck S12, S6, S9, S1, S8, S15, S14
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
Bristol Myers Squibb
- Dividends per shareFY2021: $2.01 (62.9% of profit) · FY2022: $2.19 (73.2% of profit) · FY2023: $2.31 (59.1% of profit) · FY2024: $2.42 · FY2025: $2.49 (71.5% of profit)
- Buybacks
- Dec 31, 2022: Bought back $8.0 billion of its own shares in 2022. ($8.0B)
- Dec 31, 2023: Bought back $5.2 billion of its own shares in 2023. BMS bought none in 2024, 2025 or the first nine months of 2026, and $5.0 billion of its authorization remained at Dec 31, 2025. ($5.2B)
- AuditorDeloitte & Touche LLP, since 2006
- Credit ratingMoody's and S&P (as stated in BMS's FY2025 10-K): A2 (Moody's) and A (S&P); short-term Prime-1 and A-1, outlook Stable (Feb 11, 2026)
Merck
- Dividends per shareFY2021: $2.64 (50.7% of profit) · FY2022: $2.80 (48.3% of profit) · FY2023: $2.96 · FY2024: $3.12 (45.8% of profit) · FY2025: $3.28 (44.8% of profit)
- Buybacks
- Dec 31, 2025: Bought about 59 million of its own shares for $5.1 billion in 2025. This was under a $10 billion authorization from January 2025 with no time limit, and $7.3 billion remained at Dec 31, 2025. ($5.1B)
- Sep 30, 2026: Bought $2.3 billion of its own shares in the first nine months of 2026. ($2.3B)
- AuditorPricewaterhouseCoopers LLP, since 2002
- Credit ratingMoody's and S&P (expected ratings of the May 2026 notes, per Merck's pricing term sheet): Aa3 and A+, outlook Stable (May 18, 2026)
Sources: Bristol Myers Squibb S3, S1, S14, S5 · Merck S3, S1, S6, S26
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: customer or supplier concentration, pricing, competition, execution, debt. Every risk is on each company's page.
Bristol Myers Squibb
- Cash collections fell in 2026 (liquidity)Operating cash flow was $8.7 billion in the first nine months of 2026, down $3.5 billion. BMS cites lower net customer receipts from generic erosion and the Eliquis list price cut.
Merck
- Gardasil sales in China and the US (demand)China sales fell from $6.8 billion in FY2023 to $1.9 billion in FY2025 after Gardasil shipments there were suspended. Merck expects a 2026 US public-sector purchasing benefit to largely unwind in 2027.
- Securities lawsuit (legal cases)A putative class action alleges that Merck made false and misleading statements about demand for Gardasil in China. Related derivative lawsuits are on hold.
Key facts
- How does Bristol Myers Squibb make money compared with Merck?
- Bristol Myers Squibb's revenue by segment in FY2025: Growth Portfolio 54.8%, Legacy Portfolio 45.2%. Merck's revenue by segment in FY2025: Pharmaceutical 89.4%, Animal Health 9.8%, Other 0.8%.
- Which is bigger by revenue, Bristol Myers Squibb or Merck?
- Bristol Myers Squibb reported $48.2B of revenue in FY2025, and Merck reported $65.0B in FY2025.
- How much net income did Bristol Myers Squibb and Merck report?
- Bristol Myers Squibb reported net income of $7.1B in FY2025, and Merck reported $18.3B in FY2025.
- How much of every $100 did Bristol Myers Squibb and Merck keep as net income?
- Bristol Myers Squibb kept $14.6 of every $100 that came in during FY2025, and Merck kept $28.1 in FY2025 (Cityfort calculation from each company's annual report).
- How much debt and cash do Bristol Myers Squibb and Merck have?
- Bristol Myers Squibb had $42.9B of debt and $13.0B of cash and investments on Sep 30, 2026. Merck had $53.8B of debt and $9.6B of cash and investments on Sep 30, 2026.
- When do Bristol Myers Squibb's and Merck's fiscal years end?
- Bristol Myers Squibb: December 31. Merck: December 31.
Sources: Bristol Myers Squibb S3, S4, S1, S2, S5, S8 · Merck S3, S1, S6, S4, S9, S26, S27
Built from each company's page. Bristol Myers Squibb updated Nov 6, 2026; Merck updated Nov 6, 2026.
Sources
Bristol Myers Squibb
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Bristol-Myers Squibb Company (SEC EDGAR), Feb 11, 2026
- S2Form 10-K for fiscal year 2024, Bristol-Myers Squibb Company (SEC EDGAR), Feb 12, 2025
- S3Form 10-K for fiscal year 2023, Bristol-Myers Squibb Company (SEC EDGAR), Feb 13, 2024
- S4Form 10-K for fiscal year 2022, Bristol-Myers Squibb Company (SEC EDGAR), Feb 14, 2023
- S5Form 10-Q for Q3 FY2026 (ended Sep 30, 2026), Bristol-Myers Squibb Company (SEC EDGAR), Oct 29, 2026
- S6Form 10-Q for Q2 FY2026 (ended Jun 30, 2026), Bristol-Myers Squibb Company (SEC EDGAR), Jul 30, 2026
- S7Form 10-Q for Q1 FY2026 (ended Mar 31, 2026), Bristol-Myers Squibb Company (SEC EDGAR), Apr 30, 2026
- S8Form 10-Q for Q3 FY2025 (ended Sep 30, 2025), Bristol-Myers Squibb Company (SEC EDGAR), Oct 30, 2025
- S11Earnings release, Q3 FY2026 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Oct 29, 2026
- S12Earnings release, Q2 FY2026 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Jul 30, 2026
- S13Earnings release, Q1 FY2026 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Apr 30, 2026
- S14Earnings release, Q4 FY2025 and full year 2025 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Feb 5, 2026
- S15Earnings release, Q3 FY2025 (8-K Ex. 99.1), Bristol-Myers Squibb Company (SEC EDGAR), Oct 30, 2025
- S19Proxy statement (DEF 14A) for the 2026 annual meeting, Bristol-Myers Squibb Company (SEC EDGAR), Mar 25, 2026
- S20Schedule 13G, State Street Corporation, event Jun 30, 2026, State Street Corporation (SEC EDGAR), Aug 7, 2026
- S21Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), Apr 29, 2026
- S23Schedule 13G/A, BlackRock, Inc., as of Mar 31, 2025, BlackRock, Inc. (SEC EDGAR), Apr 17, 2025
Merck
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Merck & Co., Inc. (SEC EDGAR), Feb 24, 2026
- S3Form 10-K for fiscal year 2023, Merck & Co., Inc. (SEC EDGAR), Feb 26, 2024
- S4Form 10-K for fiscal year 2022, Merck & Co., Inc. (SEC EDGAR), Feb 24, 2023
- S6Form 10-Q for Q3 FY2026 (ended Sep 30, 2026), Merck & Co., Inc. (SEC EDGAR), Nov 4, 2026
- S7Form 10-Q for Q2 FY2026 (ended Jun 30, 2026), Merck & Co., Inc. (SEC EDGAR), Aug 7, 2026
- S8Form 10-Q for Q1 FY2026 (ended Mar 31, 2026), Merck & Co., Inc. (SEC EDGAR), May 4, 2026
- S9Form 10-Q for Q3 FY2025 (ended Sep 30, 2025), Merck & Co., Inc. (SEC EDGAR), Nov 5, 2025
- S12Earnings release, Q3 FY2026 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Oct 29, 2026
- S14Earnings release, Q2 FY2026 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Aug 4, 2026
- S15Earnings release, Q1 FY2026 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Apr 30, 2026
- S16Earnings release, Q4 FY2025 and full year 2025 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Feb 3, 2026
- S17Financial tables, Q4 FY2025 (8-K Ex. 99.2), Merck & Co., Inc. (SEC EDGAR), Feb 3, 2026
- S18Earnings release, Q3 FY2025 (8-K Ex. 99.1), Merck & Co., Inc. (SEC EDGAR), Oct 30, 2025
- S22Proxy statement (DEF 14A) for the 2026 annual meeting, Merck & Co., Inc. (SEC EDGAR), Apr 8, 2026
- S23Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), Apr 30, 2026
- S24Schedule 13G/A, The Vanguard Group, event Mar 13, 2026, The Vanguard Group (SEC EDGAR), Mar 27, 2026
- S26Pricing term sheet (FWP) for $6.0 billion senior notes, May 18, 2026, Merck & Co., Inc. (SEC EDGAR), May 19, 2026
- S27Form 8-K Item 8.01, senior notes offering closed May 22, 2026, Merck & Co., Inc. (SEC EDGAR), May 22, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.